Barclays raised its target for Amgen from $380 to $400. The target remains below Amgen shares near $439, and the report gives no new company results, so it does not change Amgen's outlook.
This is a change in one firm's view, not news about Amgen's sales, drugs, or profits. The new target remains below Amgen's current share price, so the report does not clearly change the company's outlook.
Follow Amgen Inc. (AMGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AMGN